Evidence mapping of clinical research on prevention and treatment of hyperlipidemia with Chinese patent medicines_Chinese Journal of Evidence-Based Medicine

Authors：

YU Pengzhen ^1,2 , YAN Jingjing ^1,2 , LIANG Beibei ^1,2 , LI Jia ^1,2 ,  LI Bin ^1,3

1. Heart Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, P. R. China;
2. The First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou 450000, P. R. China;
3. Henan Evidence-based Chinese Medicine Center, Zhengzhou 450000, P. R. China;

Corresponding author：

LI Bin, Email: libinnvhai@163.com

Keywords：

Traditional Chinese medicine; Hyperlipidemia; Clinical research; Evidence map; Methodology

DOI：

10.7507/1672-2531.202310005

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To use the evidence map system to search and sort out the clinical research on the prevention and treatment of hyperlipidemia with proprietary Chinese medicine, and to understand the distribution of evidence in this field. Methods The literature on the treatment of hyperlipidemia with proprietary Chinese medicines was retrieved from CNKI, WanFang Data, VIP, SinoMed, PubMed, Cochrane Library, Embase and Web of Science databases from inception to December 2022. The distribution characteristics of evidence were analyzed and presented by means of text and graph. Results A total of 865 articles were included and 79 kinds of proprietary Chinese medicines were obtained. The Xuezhikang tablets or capsules were the most frequently used. In recent years, the number of published articles showed a downward trend, and the literature quality was generally low. Most of the research intervention programs only used Chinese patent medicine, and the sample size of a single study was mostly 60-100 patients, and the study course was 4-8 weeks. Clinical studies did not highlight the characteristics of traditional Chinese medicine, and only 12.7% of the studies limited the syndrome type of traditional Chinese medicine in the study population. In terms of the selection of outcome indicators, more attention was paid to blood lipid levels and safety indicators, while less attention was paid to indicators such as traditional Chinese medicine syndrome scores. Conclusion The results show that Chinese patent medicine has certain advantages in the prevention and treatment of hyperlipidemia, but there are some deficiencies in the reports of methodology and clinical characteristics, and the overall quality of the research is low.

Citation： YU Pengzhen, YAN Jingjing, LIANG Beibei, LI Jia, LI Bin. Evidence mapping of clinical research on prevention and treatment of hyperlipidemia with Chinese patent medicines. Chinese Journal of Evidence-Based Medicine, 2024, 24(9): 1061-1069. doi: 10.7507/1672-2531.202310005 Copy

1.	Yang L, Li Z, Song Y, et al. Study on urine metabolic profiling and pathogenesis of hyperlipidemia. Clin Chim Acta, 2019, 495: 365-373.
2.	Yao YS, Li TD, Zeng ZH. Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review. Lipids Health Dis, 2020, 19(1): 23.
3.	中国心血管健康与疾病报告2022概要. 中国循环杂志, 2023, 38(6): 583-612.
4.	Bułdak Ł, Marek B, Kajdaniuk D, et al. Endocrine diseases as causes of secondary hyperlipidemia. Endokrynol Pol, 2019, 70(6): 511-519.
5.	中国心血管病一级预防指南. 实用心脑肺血管病杂志, 2021, 29(1): 44, 64.
6.	Francula-Zaninovic S, Nola IA. Management of measurable variable cardiovascular disease' risk factors. Curr Cardiol Rev, 2018, 14(3): 153-163.
7.	中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年). 中国循环杂志, 2023, 38(3): 237-271.
8.	曾雨虹, 刘静, 刘军, 等. 超高危ASCVD患者的界定标准对住院ACS患者降脂治疗需求的影响. 中华心血管病杂志, 2020, 48(12): 1039-1046.
9.	Gong Y, Li X, Ma X, et al. Lipid goal attainment in post-acute coronary syndrome patients in China: results from the 6-month real-world dyslipidemia international study Ⅱ. Clin Cardiol, 2021, 44(11): 1575-1585.
10.	Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation, 2019, 140(11): e596-e646.
11.	魏停, 潘晓峰, 鄢子欣, 等. 中医药治疗高脂血症研究概况. 实用中医内科杂志, 2022, 36(7): 137-139.
12.	崔小数, 曹珊, 陈芳, 等. 高脂血症的中医研究概述. 中国中医药现代远程教育, 2020, 18(3): 139-142.
13.	马贵萍, 章怡祎. 高脂血症的中医药治疗研究进展. 中西医结合心脑血管病杂志, 2019, 17(14): 2116-2119.
14.	陈静, 谷志彬. 中成药在高脂血症治疗中的合理应用. 内蒙古中医药, 2012, 31(21): 70-71.
15.	田金徽, 李伦, 张俊华. 证据图撰写注意事项. 中国药物评价, 2019, 36(2): 81-85.
16.	Schmucker C, Motschall E, Antes G, et al. Methods of evidence mapping. a systematic review. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2013, 56(10): 1390-1397.
17.	李沐阳, 张福利, 蔡润津, 等. 证据图研究现状分析. 中国药物评价, 2019, 36(3): 161-164.
18.	中国中西医结合学会心血管病专业委员会动脉粥样硬化与血脂异常专业组. 血脂异常中西医结合诊疗专家共识. 中国全科医学, 2017, 20(3): 262-269.
19.	中国居民营养与慢性病状况报告(2020年). 营养学报, 2020, 42(6): 521.
20.	Pan L, Yang Z, Wu Y, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis, 2016, 248: 2-9.
21.	Ding W, Cheng H, Yan Y, et al. 10-year trends in serum lipid levels and dyslipidemia among children and adolescents from several schools in Beijing, China. J Epidemiol, 2016, 26(12): 637-645.
22.	木热地里·赛米. 心脑血管共患疾病血脂分布特点及危险因素分析. 乌鲁木齐: 新疆医科大学, 2022.
23.	Li X, Liu B, Duan N, et al. Clinical efficacy and safety of Chinese patent medicine combined with oseltamivir for the treatment of adult influenza: a systematic review and meta-Analysis. Am J Chin Med, 2022, 50(4): 1043-1061.
24.	Miake-Lye IM, Mak S, Lee J, et al. Massage for ain: an evidence map. J Altern Complement Med, 2019, 25(5): 475-502.
25.	李伦, 杨克虎, 田金徽, 等. 一种新的证据总结方法—证据图简介. 中国循证儿科杂志, 2011, 6(3): 230-232.
26.	韩如雪, 刘澳林, 陈贤坤, 等. 血脂康治疗高脂血症系统评价的再评价. 中药新药与临床药理, 2019, 30(1): 110-116.
27.	广东省药学会. 医疗机构超药品说明书用药管理专家共识. 中国现代应用药学, 2017, 34(3): 436-438.
28.	刘珺, 王瑱, 孔令越, 等. 复方丹参滴丸联合辛伐他汀片治疗高脂血症40例临床观察. 河北中医, 2015, (1): 93-94,158.
29.	石翠娥. 通心络治疗高脂血症的疗效观察. 实用心脑肺血管病杂志, 2011, 19(4): 599-599.
30.	任燕萍, 芦小燕, 周菲, 等. 700例药品不良反应报告超说明书用药情况分析. 中国现代应用药学, 2016, 33(11): 1474-1477.
31.	赵鸣芳. 辨病辨证并治与辨证论治的比较研究. 南京中医药大学学报, 2022, 38(8): 655-665.
32.	管慧. 中医药临床疗效评价的替代指标构建及应用—以慢性心力衰竭为例. 济南: 山东中医药大学, 2022.
33.	王新陆, 朱明军, 王建茹, 等. 基于病证结合的中医经典名方上市后评价要点. 中国中药杂志, 2021, 46(8): 2004-2009.
34.	Li JJ, Ma CS, Zhao D, et al. Lipoprotein(a) and cardiovascular disease in Chinese population: a Beijing Heart Society expert scientific statement. JACC Asia, 2022, 2(6): 653-665.
35.	程红, 肖培, 侯冬青, 等. 2017年北京市6-16岁儿童青少年血脂异常流行特征及相关因素. 中国循环杂志, 2020, 35(6): 566-572.
36.	He H, Pan L, Du J, et al. Prevalence of, and biochemical and anthropometric risk factors for, dyslipidemia in children and adolescents aged 7 to 18 years in China: a cross-sectional study. Am J Hum Biol, 2019, 31(5): e23286.
37.	汪翼. 小儿血脂异常的临床诊疗. 中国临床医生, 2013, 41(5): 5-7.
38.	向伟. 儿童青少年脂质异常血症早期预防与成人期心血管健康. 中国儿童保健杂志, 2023, 31(7): 697-702.
39.	Siri-Tarino PW, Krauss RM. Diet, lipids, and cardiovascular disease. Curr Opin Lipidol, 2016, 27(4): 323-328.
40.	张培珍. 血脂异常的中老年人调脂运动处方的研究. 北京: 北京体育大学, 2004.
41.	周洁, 向红丁, 陈伟, 等. 胰岛素抵抗和血脂异常的关系. 中国糖尿病杂志, 2010, 18(10): 740-741.
42.	王富军, 王文琦. 《中国2型糖尿病防治指南(2020年版)》解读. 河北医科大学学报, 2021, 24(12): 1365-1371.
43.	周嘉强. 糖尿病患者的血脂管理. 浙江医学, 2021, 43(21): 2275-2278, 2288.

1. Yang L, Li Z, Song Y, et al. Study on urine metabolic profiling and pathogenesis of hyperlipidemia. Clin Chim Acta, 2019, 495: 365-373.
2. Yao YS, Li TD, Zeng ZH. Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review. Lipids Health Dis, 2020, 19(1): 23.
3. 中国心血管健康与疾病报告2022概要. 中国循环杂志, 2023, 38(6): 583-612.
4. Bułdak Ł, Marek B, Kajdaniuk D, et al. Endocrine diseases as causes of secondary hyperlipidemia. Endokrynol Pol, 2019, 70(6): 511-519.
5. 中国心血管病一级预防指南. 实用心脑肺血管病杂志, 2021, 29(1): 44, 64.
6. Francula-Zaninovic S, Nola IA. Management of measurable variable cardiovascular disease' risk factors. Curr Cardiol Rev, 2018, 14(3): 153-163.
7. 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年). 中国循环杂志, 2023, 38(3): 237-271.
8. 曾雨虹, 刘静, 刘军, 等. 超高危ASCVD患者的界定标准对住院ACS患者降脂治疗需求的影响. 中华心血管病杂志, 2020, 48(12): 1039-1046.
9. Gong Y, Li X, Ma X, et al. Lipid goal attainment in post-acute coronary syndrome patients in China: results from the 6-month real-world dyslipidemia international study Ⅱ. Clin Cardiol, 2021, 44(11): 1575-1585.
10. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation, 2019, 140(11): e596-e646.
11. 魏停, 潘晓峰, 鄢子欣, 等. 中医药治疗高脂血症研究概况. 实用中医内科杂志, 2022, 36(7): 137-139.
12. 崔小数, 曹珊, 陈芳, 等. 高脂血症的中医研究概述. 中国中医药现代远程教育, 2020, 18(3): 139-142.
13. 马贵萍, 章怡祎. 高脂血症的中医药治疗研究进展. 中西医结合心脑血管病杂志, 2019, 17(14): 2116-2119.
14. 陈静, 谷志彬. 中成药在高脂血症治疗中的合理应用. 内蒙古中医药, 2012, 31(21): 70-71.
15. 田金徽, 李伦, 张俊华. 证据图撰写注意事项. 中国药物评价, 2019, 36(2): 81-85.
16. Schmucker C, Motschall E, Antes G, et al. Methods of evidence mapping. a systematic review. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2013, 56(10): 1390-1397.
17. 李沐阳, 张福利, 蔡润津, 等. 证据图研究现状分析. 中国药物评价, 2019, 36(3): 161-164.
18. 中国中西医结合学会心血管病专业委员会动脉粥样硬化与血脂异常专业组. 血脂异常中西医结合诊疗专家共识. 中国全科医学, 2017, 20(3): 262-269.
19. 中国居民营养与慢性病状况报告(2020年). 营养学报, 2020, 42(6): 521.
20. Pan L, Yang Z, Wu Y, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis, 2016, 248: 2-9.
21. Ding W, Cheng H, Yan Y, et al. 10-year trends in serum lipid levels and dyslipidemia among children and adolescents from several schools in Beijing, China. J Epidemiol, 2016, 26(12): 637-645.
22. 木热地里·赛米. 心脑血管共患疾病血脂分布特点及危险因素分析. 乌鲁木齐: 新疆医科大学, 2022.
23. Li X, Liu B, Duan N, et al. Clinical efficacy and safety of Chinese patent medicine combined with oseltamivir for the treatment of adult influenza: a systematic review and meta-Analysis. Am J Chin Med, 2022, 50(4): 1043-1061.
24. Miake-Lye IM, Mak S, Lee J, et al. Massage for ain: an evidence map. J Altern Complement Med, 2019, 25(5): 475-502.
25. 李伦, 杨克虎, 田金徽, 等. 一种新的证据总结方法—证据图简介. 中国循证儿科杂志, 2011, 6(3): 230-232.
26. 韩如雪, 刘澳林, 陈贤坤, 等. 血脂康治疗高脂血症系统评价的再评价. 中药新药与临床药理, 2019, 30(1): 110-116.
27. 广东省药学会. 医疗机构超药品说明书用药管理专家共识. 中国现代应用药学, 2017, 34(3): 436-438.
28. 刘珺, 王瑱, 孔令越, 等. 复方丹参滴丸联合辛伐他汀片治疗高脂血症40例临床观察. 河北中医, 2015, (1): 93-94,158.
29. 石翠娥. 通心络治疗高脂血症的疗效观察. 实用心脑肺血管病杂志, 2011, 19(4): 599-599.
30. 任燕萍, 芦小燕, 周菲, 等. 700例药品不良反应报告超说明书用药情况分析. 中国现代应用药学, 2016, 33(11): 1474-1477.
31. 赵鸣芳. 辨病辨证并治与辨证论治的比较研究. 南京中医药大学学报, 2022, 38(8): 655-665.
32. 管慧. 中医药临床疗效评价的替代指标构建及应用—以慢性心力衰竭为例. 济南: 山东中医药大学, 2022.
33. 王新陆, 朱明军, 王建茹, 等. 基于病证结合的中医经典名方上市后评价要点. 中国中药杂志, 2021, 46(8): 2004-2009.
34. Li JJ, Ma CS, Zhao D, et al. Lipoprotein(a) and cardiovascular disease in Chinese population: a Beijing Heart Society expert scientific statement. JACC Asia, 2022, 2(6): 653-665.
35. 程红, 肖培, 侯冬青, 等. 2017年北京市6-16岁儿童青少年血脂异常流行特征及相关因素. 中国循环杂志, 2020, 35(6): 566-572.
36. He H, Pan L, Du J, et al. Prevalence of, and biochemical and anthropometric risk factors for, dyslipidemia in children and adolescents aged 7 to 18 years in China: a cross-sectional study. Am J Hum Biol, 2019, 31(5): e23286.
37. 汪翼. 小儿血脂异常的临床诊疗. 中国临床医生, 2013, 41(5): 5-7.
38. 向伟. 儿童青少年脂质异常血症早期预防与成人期心血管健康. 中国儿童保健杂志, 2023, 31(7): 697-702.
39. Siri-Tarino PW, Krauss RM. Diet, lipids, and cardiovascular disease. Curr Opin Lipidol, 2016, 27(4): 323-328.
40. 张培珍. 血脂异常的中老年人调脂运动处方的研究. 北京: 北京体育大学, 2004.
41. 周洁, 向红丁, 陈伟, 等. 胰岛素抵抗和血脂异常的关系. 中国糖尿病杂志, 2010, 18(10): 740-741.
42. 王富军, 王文琦. 《中国2型糖尿病防治指南(2020年版)》解读. 河北医科大学学报, 2021, 24(12): 1365-1371.
43. 周嘉强. 糖尿病患者的血脂管理. 浙江医学, 2021, 43(21): 2275-2278, 2288.

Chinese Journal of Evidence-Based Medicine

Evidence mapping of clinical research on prevention and treatment of hyperlipidemia with Chinese patent medicines

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content